Do Predictors Exist for a Successful Withdrawal of Preoperative Prostaglandin E1 from Neonates with d-Transposition of the Great Arteries and Intact Ventricular Septum? by Oxenius, Angela et al.
ORIGINAL ARTICLE
Do Predictors Exist for a Successful Withdrawal of Preoperative
Prostaglandin E1 from Neonates with d-Transposition of the Great
Arteries and Intact Ventricular Septum?
Angela Oxenius • Maja I. Hug • Ali Dodge-Khatami •
Anna Cavigelli-Brunner • Urs Bauersfeld •
Christian Balmer
Received: 28 July 2010 / Accepted: 31 August 2010 / Published online: 1 October 2010
 Springer Science+Business Media, LLC 2010
Abstract Prostaglandin E1 (PGE1) is given to neonates
with d-transposition of the great arteries (d-TGA) to reduce
cyanosis by reopening and maintaining the patency of the
ductus arteriosus. To avoid side effects, this medication can
be stopped for hemodynamically stable patients after bal-
loon atrial septostomy (BAS). A consecutive series of
neonates with d-TGA and an intact ventricular septum
(IVS) presenting from 2000 through 2005 was analyzed
retrospectively to search for side effects of PGE1 and to
identify predictors for a safe preoperative withdrawal. The
medication was stopped for hemodynamically stable
patients with transcutaneous oxygen saturations higher than
80% after BAS and reinitiated for patients with an oxygen
saturation lower than 65%. Patients successfully weaned
were compared with those who had failed weaning in terms
of atrial septal defect (ASD) size, ductus arteriosus size,
and the transcutaneous oxygen saturation. Prostaglandin E1
was initiated for all 43 neonates with d-TGA. The median
maintenance dose of PGE1 was 0.00625 lg/kg/min (range,
0.00313–0.050 lg/kg/min) for a median duration of 6 days
(range, 1–12 days). For 16 patients, PGE1 was preopera-
tively withdrawn but then had to be reinitiated for 7 of the
16 patients. No predictors for a successful weaning of
PGE1 were found based on ASD size, ductus arteriosus
size, or oxygen saturation. The adverse effects of PGE1
were apnea in 10 patients and fever in 19 patients. Neither
seizures nor necrotizing enterocolitis was documented.
Prostaglandin E1 was successfully withdrawn for a
minority of hemodynamically stable patients with d-TGA.
No predictors for a successful weaning could be identified.
Because apnea and fever are common side effects, with-
drawal of PGE1 after BAS may improve patient safety and
comfort. In this patient group, if PGE1 withdrawal was not
well tolerated, it could be safely reinitiated. There were no
serious side effects of PGE1.
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Prostaglandin E1 (PGE1) is a potent vasodilator for
reopening and maintaining the patency of the ductus arte-
riosus [5]. Intravenous PGE1 is the standard of care for the
early stabilization of neonates with profound hypoxemia
and suspected ductus dependent cyanotic congenital heart
defect. Although the administration of PGE1 can be life-
saving for neonates with a ductus-dependent physiology, it
has the potential for serious side effects [3, 7, 11]. Pros-
taglandin E1 causes peripheral vasodilation in the pul-
monary and systemic circulations, with the possibility of
cutaneous flushing and clinically relevant hypotension. The
cerebral side effects of PGE1 can result in jitteriness, ele-
vated body temperature, apnea, and seizure-like activities.
In addition, PGE1 is known to affect the gastrointestinal
tract and can cause necrotizing enterocolitis. Abnormal
texture with edema and increased friability of the ductal
tissue and adjacent vessels has been noted at the time of
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surgery in patients after preoperative treatment with PGE1.
The histopathologic correlates are edema and hemorrhage
of the vessel media [4]. For the administration of PGE1, a
reliable intravenous line is required, with the potential risk
of catheter-related sepsis.
As soon as the diagnosis is suspected, neonates with
d-TGA and intact ventricular septum (IVS) are routinely
administered PGE1 to reopen the ductus arteriosus or to
maintain its patency and hence improve mixing of oxy-
genated and deoxygenated blood, with increased systemic
oxygenation before corrective surgery [10, 12]. A balloon
atrial septostomy (BAS) needs to be performed if there is
inadequate mixing at the atrial level [1]. After this inter-
vention, PGE1 can be weaned for some patients without
any adverse events. However, the optimal timing for dis-
continuation of PGE1 and predictors for a successful
withdrawal remain unclear. It also is not known whether
the risk for potential cardiac collapse after PGE1 with-
drawal outweighs the risk for potential PGE1 side effects in
the contemporary approach to an early arterial switch
operation.
We therefore conducted a retrospective analysis of
preoperative PGE1 administration for neonates with d-TGA
and IVS to define a subgroup of patients from whom PGE1
may be safely withdrawn.
Methods
This study was a retrospective analysis at a single tertiary
referral pediatric center. All consecutive neonates with
d-TGA and IVS admitted to our pediatric cardiac intensive
care unit (PICU) from January 2000 until September 2005
were included in the study. Patients with additional cardiac
malformations were excluded, but those with small ven-
tricular septal defects (\2 mm) were enrolled.
For the neonates with clinically suspected d-TGA and
IVS or an emergency echocardiographic diagnosis in the
birth clinic, PGE1 was administered immediately at a
dosage of 0.1 lg/kg/min to reopen the ductus arteriosus. At
the same time, a dopamine infusion of 4 lg/kg/min was
initiated, if necessary, to prevent severe hypotension from
PGE1 due to systemic vasodilation. The patients then were
nasotracheally intubated and transported to the intensive
care unit (ICU). The referring birth clinics are relatively
nearby, with a maximum transport duration of 2 h. Some
patients with stable hemodynamics facing a very short
transport distance were transferred while breathing
spontaneously.
At arrival in the intensive care unit, a BAS was per-
formed if the interatrial communication was deemed too
small (\5 mm) for adequate mixing of oxygenated and
deoxygenated blood, as judged by echocardiography. The
preferred access to BAS was the umbilical vein. In case of
failure, a femoral vein was used.
With a satisfactory rise in oxygen saturation and
hemodynamic stability, PGE1 was progressively tapered
down in 50% increments within 2 to 4 h and again after 4
to 8 h to a minimal dosage of 0.00625 lg/kg/min. The
PGE1 was stopped if the patient remained stable according
to individual clinical judgment and if the patient’s trans-
cutaneous oxygen saturation remained above 80%.
For deteriorating patients, PGE1 infusion was reinitiated
if the saturation dropped and remained below 65% or if
there was an increase in lactate acidosis. Cautious enteral
feeding was initiated for each patient as soon as possible.
Heart rate, respiratory rate, oxygen saturation, blood
pressure, and body temperature were regularly monitored.
We reviewed hospital charts, nursing notes, and echo-
cardiographic reports or stored echocardiographic studies
where indicated. Size of the ASD, size of the ductus arte-
riosus as measured by transthoracic echocardiography, and
transcutaneous saturation were suspected to be predictors
for a successful weaning from PGE1. The size of the ASD
was obtained after BAS by measuring the largest diameter
of the interatrial communication in the subcostal view. The
size of the ductus arteriosus was measured as the smallest
diameter of the duct obtained from a modified parasternal
view.
All measurements were taken from two-dimensional
cross-sectional echocardiography images obtained using a
12-MHz transducer (Sonos 5500, Philips Healthcare, Best,
NL). Ductus arteriosus size was measured at the time of
diagnosis and at further follow-up assessments depending
on the clinical condition. An immediate preoperative echo
scan was not routinely obtained. The mean transcutaneous
oxygen saturation was documented the first 8 h after BAS.
Possible complications of PGE1 were recorded as fol-
lows. Apneas were classified as mild or severe depending
on the need for intubation and ventilation. The need for
intubation was judged individually by the ICU team
depending on the severity of the neonate’s impaired
general condition, the neonate’s hemodynamic state, and
the signs of respiratory failure (i.e., hypoxemia or
hypercarbia).
Extubation was performed if the patient was awake and
showed appropriate behaviour, if adequate leak around the
endotracheal tube was observed, if no signs of distress were
detected during assisted spontaneous breathing with a
fraction of inspired oxygen less than 0.4, and if the patient
remained normocapnic during the weaning process. Fever
was noted if the body temperature exceeded 38C. Seizures
were judged by clinical observation. Mean arterial blood
pressure below the age-specific limits, obtained by nonin-
vasive measurement, was defined as hypotension. Irrita-
bility, trembling, or diarrhea also was documented.
Pediatr Cardiol (2010) 31:1198–1202 1199
123
For statistical analysis, the patients whose PGE1 was
withdrawn were divided into two groups: ‘‘group success’’
with successful PGE1 weaning and ‘‘group failure’’ with
failed PGE1 discontinuation. The study was approved by
the local ethics committee, and written informed consent
was obtained from the parents or legal guardians for the
data collection.
Statistical Analysis
Measurements are presented as median and range. Patient
groups were compared using the Student’s t-test and the
chi-square test where appropriate. A significant difference
was defined as a p value less than 0.05. Data were analyzed
using the statistical software SPSS 16.0 for Windows
(SPSS Inc., Chicago, IL, USA).
Results
The study population consisted of 43 patients (30 boys and
13 girls). Their median birth weight was 3,400 g (range,
1,900–4,660 g), and their median gestational age was
39.9 weeks (range, 35.1–41.7 weeks). For all 43 patients,
continuous application of PGE1 was initiated intrave-
nously. A prenatal diagnosis was available for three
patients, so continuous PGE1 administration was initiated
shortly after their birth. For 40 patients, PGE1 was initiated
on clinical suspicion at a median time of 5 h (range,
2–110 h) after birth. A loading dose of 0.1 lg/kg/min was
given to 23 patients. The median maintenance dose of
0.00625 lg/kg/min (range, 0.00313–0.050 lg/kg/min)
given for a median duration of 6 days (range, 1–12 days).
Mechanical ventilation was initiated primarily for
resuscitation or safety during transfer of 41 patients for a
median duration of 3 days (range, 1–8 days). At arrival in
our PICU, BAS was performed for 40 patients with a
restrictive ASD at a median time of 9 h (range, 2–120 h)
after birth. The median ASD size after BAS was 6 mm
(range, 3.5–9 mm).
Vascular access was via the umbilical vein in 18 of 40
patients and via the femoral vein in 18 patients. For four
patients, information regarding vascular access was miss-
ing. The median oxygen saturation before BAS was 70%
(range, 40–85%) and increased to 80% (range, 40–90%)
1 day after BAS.
For 16 patients, PGE1 was gradually withdrawn within a
median time of 5 days (range, 1–12 days). This preopera-
tive strategy was successful for nine patients (‘‘group
success’’) who remained stable without any further PGE1
administration until corrective surgery was performed.
However, PGE1 had to be reinitiated in seven patients for
severe cyanosis (‘‘group failure’’) (Fig. 1). The cessation of
PGE1 could not be predicted by size of the ASD after BAS,
size of the ductus arteriosus, or transcutaneous oxygen
saturation (Table 1).
For 15 hemodynamically unstable patients, catechola-
mins (dobutamine, epinephrine, and norepinephrine) were
administered at a low dosage. Antibiotic therapy was ini-
tiated at birth for 18 of the 43 patients, and discontinued for
all the patients after 48 h when negative blood cultures
were obtained.
Major complications of PGE1 such as apnea requiring
reintubation, necrotizing enterocolitis, or convulsions were
not observed in our study population. For 10 of the 43
patients, milder apnea occurred. After BAS, a low dosage
Total
N = 43 
 PGE1 continued: 
n = 27 
PGE1 withdrawn:
n = 16 
Successful 
n = 9 
Failed and reinitiated
n = 7 
Fig. 1 Number of observed patients with transposition of the great
arteries (TGA) and intact ventricular septum (IVS), prostaglandin E1
(PGE1) management, and outcome
Table 1 Analysis of patients whose prostaglandin E1 (PGE1) was
withdrawn: comparison of ‘‘group success’’ versus ‘‘group failure’’ in
terms of demographic data and possible predictors
Group success:
PGE1 withdrawal
successful
n (range)
Group failure:
PGE1 withdrawal
failed n (range)
p value
No. of patients 9 7
Gestational age
(weeks)
38.7 (35.1–40.7) 39.9 (36.9–41.1) 0.57
Weight at birth (kg) 3.2 (1.9–3.8) 3.7 (2.6–4.7) 0.12
Apgar at 5 min 8 (8–10) 9 (7–10) 0.74
Antenatal diagnosis 2 0 0.20
Age at diagnosis (h) 9 (2–43) 11 (3–120) 0.30
Ductus arteriosus
size (mm)a
3.5 (3–5) 4 (2.8–6) 0.78
ASD size (mm)b 6 (4–9) 5.5 (3.5–7.5) 0.40
SO2 before BAS (%) 75 (60–85) 70 (50–80) 0.28
SO2 1 day after
BAS (%)
85 (75–90) 80 (70–85) 0.14
Values are given as n or as median (range) respectively
a Ductus arteriosus size: smallest diameter of the ductus arteriosus as
measured by echocardiogaphy on the day of BAS
b ASD size: largest diameter of the ASD immediately after BAS
ASD atrial septal defect, SO2 oxygen saturation, BAS balloon atrial
septostomy
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of inotropic drugs was necessary for 19 of the patients still
receiving PGE1. Fever was reported for 19 of the patients
as a possible side effect of PGE1. Irritability was docu-
mented in 9 of the patients.
The arterial switch operation was performed at a median
age of 7 days (range, 4–13 days). All the patients went to
the operating room in a stable condition. None of the
operations were complicated by tissue fragility or swelling,
as observed intraoperatively by the surgeons.
Discussion
In different centers, large variations in the protocol for
PGE1 administration and timing of surgery for d-TGA can
be found. At the same time, few data are published
regarding the optimal timing of potential PGE1 cessation.
In the first part of this study, we focused on a group of
neonates with d-TGA after successful BAS with adequate
interatrial mixing whose PGE1 could safely be withdrawn
before surgery. The results of our study suggest that failure
of weaning from PGE1 cannot be properly estimated
beforehand by clinical or echocardiographic data.
After cessation of PGE1, the ductus arteriosus constricts
and eventually closes spontaneously. Therefore, the mixing
of oxygenated and deoxygenated blood will decrease at the
level of the ductus arteriosus and be limited to the intera-
trial mixing. In this situation, the amount of shunted blood
is determined by the size of the ASD and the atrial filling
pressures, which again depend primarily on ventricular
performance, heart rate, and peripheral vascular resistances
of the systemic and pulmonary circulations. In hemody-
namically stable patients with d-TGA and IVS, the size of
the ASD could therefore be a fairly good predictor of
interatrial mixing. However, the atrial filling pressures and
its determinants were not taken into account in this retro-
spective study.
The most striking hemodynamic change within the first
days of life is the natural fall in pulmonary vascular
resistance during the physiologic process of transitional
circulation. This process can be rapidly fluctuating, par-
ticularly in sick neonates after sustained postnatal hypox-
emia. Prostaglandin E1, known to be a potent pulmonary
vasodilator [2, 5], will therefore contribute to an increased
pulmonary blood flow and an overall more stable hemo-
dynamic condition. At discontinuation of PGE1, the initial
pulmonary vasoconstricion may reappear and increase
right-to-left shunting at the ductus arteriosus and ASD
levels.
In a population of 45 neonates with d-TGA and IVS, Finan
et al. [3] reported a significantly higher incidence of rebound
hypoxemia at aggressive discontinuation of the PGE1 infu-
sion after BAS. This clinical observation was attributed to
the changes in pulmonary vascular resistance by PGE1. It is
probable that in the ‘‘group success’’ of our study with
achieved cessation of PGE1, the pulmonary vascular resis-
tance had already decreased, enabling increased pulmonary
blood flow. On the other hand, in the ‘‘group failure,’’
increased pulmonary vascular resistance may have persisted
and prevented the cessation of PGE1 despite adequate mix-
ing of oxygenated and deoxygenated blood.
Retrospectively, we cannot evaluate whether the
rebound hypoxemia after cessation of PGE1 was due to
ductus arteriosus closure or increased pulmonary vascular
resistance. The retrospective design of this study prohibited
a direct measurement of the pulmonary vascular resistance.
Furthermore, the residual shunting at the level of the ductus
arteriosus cannot be properly estimated due to the com-
plexity of the process of dilation and constriction of the
ductus arteriosus.
In the second part of the study, we focused on side
effects of PGE1 in the whole study population of 43
patients. Significant side effects of PGE1 are reported to
occur in 23% to 50% of patients with congenital heart
defect [8]. In our study population, severe side effects (i.e.,
seizure-like episodes and necrotizing enterocolitis) were
not observed. When various studies of PGE1 side effects
are compared, the findings seem to indicate that serious
adverse events are limited to at-risk populations and to
patients who require high maintenance doses of PGE [8, 9].
Our study did not include patients with additional risk
factors, and the maintenance dose of PGE1 was kept low.
In our study population, an involvement of the central
nervous system was frequently observed. A certain amount
of jitteriness and hyperreactivity was noted in most of the
neonates receiving PGE1, although this was difficult to
quantify retrospectively. Seizures did not occur. In the
study of Lewis et al. [7], central nervous system events
were observed more often in acidotic patients and in those
with a longer duration of PGE1 infusion. The highest
incidence of seizure-like activities was noted in the study
of Ohara et al. [9], but it is not obvious from this study
whether these patients had additional risk factors such as
asphyxia or prematurity.
The highest incidence of necrotizing enterocolitis was
reported by Singh et al. [11]. In their study, 7 of 34 patients
treated with PGE1 were affected. Four of these seven
patients were found in the high-risk population of pre-
mature neonates.
Our incidence of apnea was within the range of other
reports [7–9, 11], and mechanical ventilation for prolonged
apnea was not necessary for any of our patients. One-fourth
of all neonates to whom PGE1 is administered will expe-
rience apnea, highlighting the need for close cardiopul-
monary monitoring of these patients in an intensive care,
intermediate care, or neonatal unit.
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Notably, none of our study patients had tissue alterations
(i.e., swelling and tissue fragility) at the time of surgery,
which could complicate surgical repair. This side effect has
been reported in older studies, in which PGE1 was
administered over a longer period [4, 6]. Reducing the
exposure to PGE1 not only by earlier surgical correction
but also by a lowered dosage as we aimed to achieve for
our patient population may have contributed to our sur-
geons’ subjective impression of normal tissue handling
during the arterial switch operation, although our study had
neither a control group nor histopathologic findings.
Our study is limited by the fact that the subgroups of
patients whose PGE1 was withdrawn are too small to show
a significant difference in the statistical analysis. Further-
more, the impact of PGE1 on pulmonary vascular resis-
tance remains speculative because a direct measurement of
pulmonary artery pressure and flow was not obtained.
Conclusions
To improve patient comfort and to reduce potential PGE1-
related morbidity, an effort should be made to withdraw
PGE1 preoperatively in stable neonates with d-TGA after
BAS. Patients should be monitored closely thereafter
because the resulting hemodynamic course cannot be pre-
dicted from the ASD size, ductus arteriosus size, or oxygen
saturation after BAS. In case of rebound hypoxemia in our
study, PGE1 could be safely reinitiated in this small patient
group and had minimal side effects with low-dose
administration.
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